Compare Ingersoll Rand (IR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ingersoll Rand vs State Street SPDR S&P Biotech ETF — how do they compare? Ingersoll Rand trades at $78.16 (market cap $29.97B), while State Street SPDR S&P Biotech ETF trades at $149.94 (market cap $10.08B). The key difference: Ingersoll Rand is far larger — about 3× State Street SPDR S&P Biotech ETF's market cap, and Ingersoll Rand pays a 0.1% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ingersoll Rand for 7 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| IR | XBI | |
|---|---|---|
Market Cap | $29.97B | $10.08B |
Volume | 4,688,805 | 9,534,635 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $98.76 | $169.55 |
52-Week Low | $68.54 | $104.99 |
Typical Hold Time | 7 Days | 37 Days |
Enterprise Value | $33.63B | — |
Dividend Yield | 0.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $150.23, down 0.44% on the day, with bearish technical signals dominating. The ETF faces resistance near $152-154 while finding support at $147-149 levels. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech sector optimism from M&A activity and cancer vaccine breakthroughs. The fund's 0.35% expense ratio compares unfavorably to broader healthcare ETFs but offers targeted biotech exposure.
Outlook remains mixed with technical weakness offset by sector catalysts. The biotech focus provides growth potential but carries higher volatility than diversified healthcare alternatives. Key risks include sector-specific regulatory pressures and the fund's expense structure, while opportunities exist from ongoing pharmaceutical innovation and capital market improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ingersoll Rand
Ingersoll Rand develops industrial technologies for creating and managing flow, pressure, and motion. Its portfolio includes compressors, pumps, vacuum systems, and other equipment used across industrial markets.
Read more on IR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
